Denosumab plus romosozumab vs denosumab only was associated with improved bone mineral density among patients with severe postmenopausal osteoporosis.

Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event, ...

On April 23, Biocon board approved the raising of funds up to Rs 4,500 crore via the issuance of equity shares, ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...

Denosumab biosimilars Stoboclo and Osenvelt were approved for osteoporosis and bone loss, demonstrating comparable efficacy and safety to reference drugs. Guselkumab, the first IL-23 inhibitor ...

Total hip BMD increases were associated with reduced risk for vertebral and all clinical fractures across active control or sequential therapy trials.

Biocon Biologics Ltd receives positive CHMP opinions for denosumab biosimilars Vevzuo and Denosumab BBL, advancing bone health treatments.

Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market. Amgen sells ...

Pharma stocks Zydus Life, Aurobindo Pharma and Biocon gained up to nearly 3% in trade after they secured regulatory approvals ...

FDA committee recommends Amgen's denosumab, for the treatment, but not prevention, of bone loss, while Lilly decides not to submit arzoxifene for regulatory review after 5-year trial. Later this ...

Among patients with severe postmenopausal osteoporosis unresponsive to long-term denosumab, addition of romosozumab improved lumbar spine bone mineral density. Denosumab combined with romosozumab ...